Skip to content

The role of Moringa and Acemmanen in accelerating wound healing

The role of Moringa and Acemmanen in accelerating healing and alveolar socket regeneration after teeth extraction; randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN48008836
Enrollment
30
Registered
2023-11-07
Start date
2023-06-07
Completion date
Unknown
Last updated
2023-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healing and alveolar socket regeneration after teeth extraction Oral Health

Interventions

It will include a total of 15 patients in each group who need extraction of one posterior maxillary tooth in the right maxilla and one posterior tooth in the left maxilla. One group will receive the M

Sponsors

Umm al-Qura University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects must voluntarily sign the informed consent. 2. Subjects must be male or female who are at least 19–50 years of age. 3. Subjects must be able and willing to follow study procedures and instructions. 4. Subjects must have no systemic diseases or any other condition that may affect the bone healing or interfere with the periodontal health. 5. Subjects must have no history of using systemic antibiotics or non-steroidal anti-inflammatory agents during the last 6 months. 6. The same type of tooth should be on both sides, either two anterior or two premolars or two molars. 7. Teeth extractions must be completed successfully at College of Dental Medicine at Umm Al-Qura University (i.e. Department of Oral and Maxillofacial Surgery). 8. No fragment of root should be left in the jaw. 9. Four walls of the tooth socket should be present after extraction.

Exclusion criteria

Exclusion criteria: 1. Existence of any systemic condition such as uncontrolled diabetes mellitus, cancer, disorders that compromise wound healing, history of radiation therapy of the head and neck area, chronic steroid therapy, intravenous and oral bisphosphonate therapy, bone diseases, immunosuppressive therapy or any other condition that would contraindicate oral surgical treatment. 2. Pregnant or lactating women or who plan to become pregnant during the study. 3. Subjects who have failed to maintain good oral hygiene and plaque control. 4. Allergy or hypersensitivity to any products used throughout the study (Moringa extract or Acemannan or collagen membrane). 5. Presence of =3 mm of vertical loss of the buccal bone in relation to the palatal wall. 6. Subjects with active periodontitis. 7. Presence of acute dentoalveolar infections in the teeth involved in the study. 8. Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day) or chew tobacco or use any tobacco product within 3 months prior to enrollment. 9. Subjects who have para-functional habits. 10. Subjects with lesions, abnormalities, or variations in anatomical landmarks, especially in the sinus. 11. Subjects with circumstances, in the opinion of the investigator, which would prevent completion of study participation, such as history of noncompliance or unreliability.

Design outcomes

Primary

MeasureTime frame
Bucco-palatal width & vertical height of the alveolar ridge measured using Cone beam computed tomography (CBCT) which performed before the tooth and after 3 months following the tooth extractions.

Secondary

MeasureTime frame
Baseline and follow-up visits. They are as followed : visit 2 (baseline, enrollment, randomization), visit 3 (Follow up (F/U) at 24hr), visit 4 (F/U at the 3rd day), visit 5 (F/U at the 10th day) and visit 6 (F/U at 3 months) 1. Socket wound healing will be assessed using Landry, Turnbull, and Howley index (LWHI) measured at baseline and follow-up visits. 2. Changes in PD, CAL, BoP and gingival rescission measured using periodontal probe in addition to clinical examination at baseline and follow-up visits 3. Subject satisfaction will be assessed using a Visual Analogue Scale (VAS) (scored from 0–100) at the baseline and follow-up visits. 4. Complications (swelling, suppuration, pain, infection, etc.) measured using examination kit and clinical examination at baseline and follow-up visits

Countries

Saudi Arabia

Contacts

Public ContactAbrar Demyati
akdemyati@uqu.edu.sa+966 503226669

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026